117 related articles for article (PubMed ID: 38168678)
21. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
22. Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method.
Shinmei S; Sentani K; Hayashi T; Sakamoto N; Goto K; Oo HZ; Naito Y; Teishima J; Matsubara A; Oue N; Kuniyasu H; Yasui W
Urol Oncol; 2014 Aug; 32(6):769-78. PubMed ID: 24968948
[TBL] [Abstract][Full Text] [Related]
23. Cholesterol-modified poly(lactide-co-glycolide) nanoparticles for tumor-targeted drug delivery.
Lee JJ; Lee SY; Park JH; Kim DD; Cho HJ
Int J Pharm; 2016 Jul; 509(1-2):483-491. PubMed ID: 27286639
[TBL] [Abstract][Full Text] [Related]
24. Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer.
Sherif AY; Harisa GI; Shahba AA; Alanazi FK; Qamar W
Molecules; 2023 Jan; 28(1):. PubMed ID: 36615641
[TBL] [Abstract][Full Text] [Related]
25. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
26. Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics.
Madajewski B; Chen F; Yoo B; Turker MZ; Ma K; Zhang L; Chen PM; Juthani R; Aragon-Sanabria V; Gonen M; Rudin CM; Wiesner U; Bradbury MS; Brennan C
Clin Cancer Res; 2020 Oct; 26(20):5424-5437. PubMed ID: 32723835
[TBL] [Abstract][Full Text] [Related]
27. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced.
Song X; Wang J; Xu Y; Shao H; Gu J
Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022
[TBL] [Abstract][Full Text] [Related]
28. Erythrocyte membrane-camouflaged gefitinib/albumin nanoparticles for tumor imaging and targeted therapy against lung cancer.
Wen Q; Zhang Y; Muluh TA; Xiong K; Wang B; Lu Y; Wu Z; Liu Y; Shi H; Xiao S; Fu S
Int J Biol Macromol; 2021 Dec; 193(Pt A):228-237. PubMed ID: 34688683
[TBL] [Abstract][Full Text] [Related]
29. Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo.
Liu J; Zhang R; Su T; Zhou Q; Gao L; He Z; Wang X; Zhao J; Xing Y; Sun F; Cai W; Wang X; Han J; Qin R; Désaubry L; Han B; Chen W
J Exp Clin Cancer Res; 2023 May; 42(1):128. PubMed ID: 37210546
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of targeted curcumin (CUR) loaded PLGA nanoparticles for in vitro photodynamic therapy on human glioblastoma cell line.
Jamali Z; Khoobi M; Hejazi SM; Eivazi N; Abdolahpour S; Imanparast F; Moradi-Sardareh H; Paknejad M
Photodiagnosis Photodyn Ther; 2018 Sep; 23():190-201. PubMed ID: 29969678
[TBL] [Abstract][Full Text] [Related]
31. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
32. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer.
Yallapu MM; Khan S; Maher DM; Ebeling MC; Sundram V; Chauhan N; Ganju A; Balakrishna S; Gupta BK; Zafar N; Jaggi M; Chauhan SC
Biomaterials; 2014 Oct; 35(30):8635-48. PubMed ID: 25028336
[TBL] [Abstract][Full Text] [Related]
33. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
34. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
35. [Mechanisms of drug resistance in endocrinotherapy for castration-resistant prostate cancer].
Bo B; Guo JB; Liu LR; Wei Q
Zhonghua Nan Ke Xue; 2021 Feb; 27(2):167-171. PubMed ID: 34914335
[TBL] [Abstract][Full Text] [Related]
36. Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC).
Li Y; Shi H; Zhao Z; Xu M
BMC Urol; 2022 Oct; 22(1):162. PubMed ID: 36258196
[TBL] [Abstract][Full Text] [Related]
37.
Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
[TBL] [Abstract][Full Text] [Related]
38. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
40. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
